Common use of Stipulated Penalties for Failure to Comply with Certain Obligations Clause in Contracts

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK fails to establish and implement any of the following obligations as described in Section III: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Board; d. the management accountability and certification obligations; e. a written Code of Conduct; f. written Policies and Procedures; g. the training of Covered Persons, Relevant Covered Persons, Management, and Board Members; h. a TRACER program; i. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK Indivior and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) per obligation for each day GSK Indivior fails to establish and establish, implement or comply with any of the following obligations as described in Section III: a. a Compliance Officer; b. a Compliance Committee; c. the Board NGC compliance obligationsobligations and the engagement of a Compliance Expert, including the resolution from performance of a Compliance Program Review, and the Boardpreparation of a Compliance Program Review Report, as required by Section III.A.3; d. the management accountability certification obligations and certification obligationsthe development and implementation of a written process for Certifying Employees, as required by Section III.A.4; e. a written Code of Conduct; f. written Policies and Procedures; g. f. the development of a written training plan and the training and education of Covered Persons, Relevant Covered Persons, Management, Persons and Board MembersNGC members; g. a risk assessment and mitigation process; h. a TRACER program; i. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK CCH and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK CCH fails to establish and implement any of the following obligations as described in Section IIISections III and IV: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Boarda Chief Quality Officer; d. the Governing Authority compliance obligations and the engagement of a Compliance Expert, the performance of a Compliance Program Review, and the preparation of a Compliance Program Review Report; e. the management accountability and certification obligations; e. f. a written Code of Conduct; f. g. written Policies and Procedures; g. h. the development and/or implementation of a Training Plan for the training of Covered Persons, Relevant Covered Persons, Management, and Board Governing Authority Members; i. a risk assessment and internal review process as required by Section III.E; h. a TRACER program; i. j. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK ICH and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK ICH fails to establish and implement any of the following obligations as described in Section IIISections III and IV: a. a Compliance Officer; b. a Compliance Committee; c. the Board of Directors compliance obligations, including the resolution from the Board; d. the management accountability and certification obligations; e. a written Code of Conduct; f. written Policies and Procedures; g. the development and/or implementation of a Training Plan for the training of Covered Persons, Relevant Arrangements Covered Persons, Management, and Board Members; h. the Focus Arrangements Procedures and/or Focus Arrangements Requirements described in Sections III.D.1 and III.D.2; i. a risk assessment and internal review process as required by Section III.F; h. a TRACER program; i. j. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK IHS and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK IHS fails to establish and implement any of the following obligations as described in Section IIISections III and IV: a. a Compliance Officer; b. a Compliance Committee; c. the Board of Directors compliance obligations, including the resolution from the Board; d. the management accountability and certification obligations; e. a written Code of Conduct; f. written Policies and Procedures; g. the development and/or implementation of a Training Plan for the training of Covered Persons, Relevant Arrangements Covered Persons, Management, and Board Members; ; h. a TRACER program; the Focus Arrangements Procedures and/or Focus Arrangements Requirements described in Sections III.D.1 and III.D.2; i. a Disclosure Programrisk assessment and mitigation process as required by Section III.F;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK Life Spine and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties on Life Spine (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) per obligation for each day GSK Life Spine fails to establish and establish, implement or comply with any of the following obligations as described in Section III: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Board; d. the management accountability engagement of a Compliance Expert, the performance of a Compliance Program Review, and certification obligationsthe preparation of a Compliance Program Review Report, as required by Section III.A.3.d; e. the management certification obligations and the development and implementation of a written Code of Conductprocess for Certifying Employees, as required by Section III.A.4; f. written Policies and Procedures; g. the development of a written training plan and the training and education of Covered Persons, Relevant Covered Persons, Management, Persons and Board Membersmembers; h. a TRACER programrisk assessment and internal review process; i. a Disclosure Program; j. Ineligible Persons screening and removal requirements; k. notification of Government investigations or legal proceedings; l. reporting of Reportable Events;

Stipulated Penalties for Failure to Comply with Certain Obligations. ‌ As a contractual remedy, GSK KRHS and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK KRHS fails to establish and establish, implement or comply with any of the following obligations as described in Section Sections III: a. a Compliance Officer;Officer;‌ b. a Compliance Committee;Committee;‌ c. the Board of Directors compliance obligations, including the resolution from the Board;obligations;‌ d. the management accountability and certification obligations;, as required by Section III.A.4;‌ e. a written Code of Conduct; f. written Policies and Procedures;Procedures;‌ g. f. the development of a written training plan and the training and education of Covered Persons, Relevant Arrangements Covered Persons, Management, and Board Members;members;‌ g. the Focus Arrangements Procedures and/or Focus Arrangements Requirements;‌ h. a TRACER program; risk assessment and internal review process‌ i. a Disclosure Program;Program;‌

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK Progenity and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) per obligation for each day GSK Progenity fails to establish and establish, implement or comply with any of the following obligations as described in Section Sections III: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Boardobligations as required by Section III.A.3.; d. the management accountability certification obligations and certification obligationsthe development and implementation of a written process for Certifying Employees, as required by Section III.A.4; e. a written Code of Conduct; f. written Policies and Procedures; g. f. the development of a written training plan and the training and education of Covered Persons, Relevant Arrangements Covered Persons, Management, and Board Membersmembers; g. the Focus Arrangements Procedures and/or Focus Arrangements Requirements; h. a TRACER program; i. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK WellCare and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK WellCare fails to establish and implement any of the following obligations as described in Section III: a. a Chief Compliance Officer; b. a Corporate Compliance Committee; c. the Board compliance obligations, including the resolution from the BoardCompliance Liaisons; d. the management accountability and certification obligationsa Board Regulatory Compliance Committee; e. Compliance Program Review Assessment; f. Board Regulatory Compliance Committee Resolution; g. Certifying Employee certification; h. a written Code of Conduct; f. i. written Policies and Procedures; g. j. the training of Covered Persons, Persons and Relevant Covered Persons, Management, and Board Members; h. a TRACER program; i. k. a Disclosure Program; 1. Ineligible Persons screening and removal requirements;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK OCOM and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) per obligation for each day GSK OCOM fails to establish and establish, implement or comply with any of the following obligations as described in Section Sections III: a. a an OCOM Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from performance of a Compliance Program Review, and the Boardpreparation of a Compliance Program Review Report, as required by Section III.A.3; d. the management accountability certification obligations and certification obligationsthe development and implementation of a written process for Certifying Employees, as required by Section III.A.4; e. a written Code of Conduct; f. written Policies and Procedures; g. f. the development of a written training plan and the training and education of Covered Persons, Relevant Arrangements Covered Persons, Management, and Board Membersmembers; g. the Focus Arrangements Procedures and/or Focus Arrangements Requirements; h. a TRACER program; i. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK Lilly and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK Lilly fails to establish and implement establish, implement, or accomplish any of the following obligations as described in Section III: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Committee of the Board; d. the management accountability and certification obligations; e. a written Code of Conduct; f. e. written Policies and Procedures; g. f. the training of Covered Persons, Persons and Relevant Covered Persons, Management, and Board Members; g. a Disclosure Program; Corporate Integrity Agreement Xxx Xxxxx Company h. a TRACER programIneligible Persons screening and removal requirements; i. notification of Government investigations or legal proceedings; j. notification of written communications with FDA as required by Section III.I; k. a Disclosure Programreview of records reflecting the content of detailing sessions; l. a program for FFMP;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK RMS and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) per obligation for each day GSK RMS fails to establish and establish, implement or comply with any of the following obligations as described in Section III: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Board; d. the management accountability certification obligations and certification obligationsthe development and implementation of a written process for Certifying Employees, as required by Section III.A.4; e. a written Code of Conduct; f. written Policies and Procedures; g. f. the development of a written training plan and the training and education of Covered Persons, Relevant Covered Persons, Management, Persons and Board Membersmembers; g. a risk assessment and internal review process; h. a TRACER programDisclosure Program; i. a Disclosure ProgramIneligible Persons screening and removal requirements; j. notification of Government investigations or legal proceedings; k. reporting of Reportable Events; l. notification of written communications with FDA; m. the FFMP;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK ION and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK ION fails to establish and establish, implement or comply with any of the following obligations as described in Section III: a. a Compliance Officer; b. a Compliance Committee; c. the Board compliance obligations, including the resolution from the Boardan Arrangements Officer; d. the Board of Directors compliance obligations; e. the engagement of a Compliance Expert, the performance of a Compliance Program Review, and the preparation of a Compliance Program Review Report; f. the management accountability and certification obligations; e. a written Code of Conduct; f. g. written Policies and Procedures; g. the h. training and education of Covered Persons, Relevant Arrangements Covered Persons, ManagementION Physician-Investors, and Board Members; i. the ION Physician-Investor Certification Statements; j. the Selection Process and Selection Criteria Procedures, the Focus Arrangements Procedures and/or Focus Arrangements Requirements; h. a TRACER program; i. a Disclosure Program;

Stipulated Penalties for Failure to Comply with Certain Obligations. As a contractual remedy, GSK Memorial Health and OIG hereby agree that failure to comply with certain obligations as set forth in this CIA may lead to the imposition of the following monetary penalties (hereinafter referred to as “Stipulated Penalties”) in accordance with the following provisions. 1. A Stipulated Penalty of $2,500 (which shall begin to accrue on the day after the date the obligation became due) for each day GSK Memorial Health fails to establish and implement any of the following obligations as described in Section IIISections III and IV: a. a Compliance Officer; b. a Compliance Committee; c. the Board of Directors compliance obligationsobligations and the engagement of a Compliance Expert, including the resolution from performance of a Compliance Program Review, and the Boardpreparation of a Compliance Program Review Report, as required by Section III.A.3; d. the management accountability and certification obligations; e. a written Code of Conduct; f. written Policies and Procedures; g. the development and/or implementation of a Training Plan for the training of Covered Persons, Relevant Arrangements Covered Persons, Management, and Board Members; h. the Focus Arrangements Procedures and/or Focus Arrangements Requirements described in Sections III.D.1 and III.D.2; i. a TRACER programrisk assessment and internal review process as required by Section III.F; i. j. a Disclosure Program;